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Abstract: In the era of tyrosine kinase inhibitors, resistance still constitutes a problem in chronic myeloid leukemia (CML) patients;
thus, new pathway-specific inhibitors like miRNAs have become important in the treatment of refractory patients. There are no
satisfying data regarding the miRNAs and anti-miRNA treatment targeting STAT5A and 5B. In this study, we first researched the effect
of dasatinib on apoptosis in the CML cell line K562. The expressions of miRNAs possibly targeting both STAT5A and 5B were then
determined. The down- and upregulation of the miRNAs were compared using the ΔΔCT method. At the last stage of the study, we used
a new primer probe in order to validate the results. The level of hsa-miR-940 was decreased 4.4 times and the levels of hsa-miR-527 and
hsa-miR-518a-5p were increased 12.1 and 8 times, respectively, in the dasatinib-treated group when compared to the control group.
We detected similar results in the validation step. As a conclusion, we determined the expression profiles of miRNAs targeting STAT5A
and 5B that had an important role in the pathogenesis of CML. The data obtained could lead to determining new therapeutic targets
for CML patients.
Key words: miRNA expressions, STAT5A, STAT5B, chronic myeloid leukemia, dasatinib, K562 cells

1. Introduction
Chronic myeloid leukemia (CML) is a hematologic
malignancy characterized by the presence of a reciprocal
chromosomal translocation of the Abelson (ABL1)
oncogene on the 9th chromosome and a breakpoint cluster
region (BCR) on the 22nd chromosome, resulting in t(9,22).
This results in chimeric fusion, producing oncoprotein
BCR–ABL with tyrosine kinase activity (Groffen et al.,
1984). The subsequent uncontrolled tyrosine kinase
activity results in excess activation of multiple signaling
pathways such as RAS/RAF/MAPK, PI3K/Akt, JUN,
MYC, and Janus kinase/signal transducers and activators
of transcription (JAK/STAT), leading to persistent cell
proliferation, reduced apoptosis, and malignant expansion
of pluripotent stem cells in bone marrow (Steelman et al.,
2004).
Since CML is due to a well-recognized translocation,
it is possible to inhibit the aberrant BCR–ABL tyrosine
kinase (TK) activity using molecularly targeted therapies.
* Correspondence: fergunaydin@hotmail.com
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Imatinib was the ﬁrst BCR–ABL TK inhibitor (TKI)
introduced for the treatment of CML (Kantarjian et al,
2002). Although imatinib and other second-generation
(including dasatinib and nilotinib) and third-generation
TKIs are generally well tolerated, ensuing resistance
remains a major clinical challenge (Apperley, 2007).
Cytokines and growth factors can activate the JAK/
STAT signaling pathway, which has been well investigated
in CML. Thus, the cascade transmits information from
extracellular chemical signals to the nucleus, resulting in
DNA transcription and expression of genes involved in
immunity, proliferation, cellular migration, angiogenesis,
differentiation, apoptosis, and oncogenesis (Rawlings
et al., 2004). Therefore, overexpression of STATs,
especially STAT5, is associated with leukemogenesis and
carcinogenesis (Bowman et al., 2000; Rawlings et al.,
2004). BCR/ABL chimeric protein constitutively activates
the JAK/STAT cascade and causes antiapoptotic activity
and uncontrolled proliferation of the malignant clone
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(Benekli et al., 2009). Accordingly, suppression of STATs
results in inhibition of leukemogenesis and apoptosis of
tumor cells including CML, which makes STAT proteins
ideal targets for emerging cancer therapies (Steelman et
al., 2004; Yu and Have, 2004; Kosova et al., 2010). In this
regard, it is imperative to target the uncontrolled STAT
proteins without affecting normal cells. In this setting, new
treatment strategies such as microRNAs (miRNAs) attract
a great deal of attention.
miRNAs are small endogenously synthesized
noncoding RNA sequences with 19–24 nucleotides.
Over 2000 miRNAs reported in humans regulate gene
expression by binding to a 3’-untranslated region
(3’UTR) within target messenger RNAs (mRNAs) and
inducing translational repression or RNA destabilization
(Bartel, 2004). Through this mechanism, they regulate
many cellular processes such as cellular proliferation,
differentiation, apoptosis, metabolic activities, and
immunity (Cheng et al., 2005; Spizzo et al., 2009; Farazi
et al., 2011). More than 50% of miRNAs reported in
humans are located at specific chromosomes that are
associated with several cancers (Calin and Croce, 2006),
including hematologic malignancies (Calin et al., 2002);
thus, dysregulation of miRNAs seems to play a key role
in carcinogenesis (Spizzo et al., 2009). In light of these
observations, it appears that these small molecules may
potentially be exploited for prognostic, diagnostic, or
therapeutic purposes in patients with neoplastic disorders,
including hematologic malignancies and solid tumors such
as lymphoma and leukemia, as well as breast, lung, gastric,
and pancreatic cancers (Avery-Kiejda et al., 2014; Miao et
al., 2014; Troppan et al., 2014; Zheng et al., 2014). In CML
patients, several miRNAs such as miR-29b, miR-138, and
miR-130a/b, which were up- or downregulated aberrantly,

were reported as either oncogene or tumor suppressors
(Suresh et al., 2011; Li et al., 2013; Xu et al., 2014).
In this study, we analyzed the miRNAs that are
potential targets of STAT5A and STAT5B and varying
expression profiles of these determined miRNAs in
CML cell line model K562 cells treated with dasatinib
or not. Furthermore, apoptosis associated with dasatinib
treatment in leukemic cells was explored.
2. Materials and methods
2.1. Culturing conditions of cells and dasatinib treatment
Cell line K562 “human CML” (the characteristics of the
K562 cell line are provided in Table 1) was purchased from
ECACC (European Collection of Cell Cultures) and was
cultured in RPMI 1640 medium containing 10% (v/v)
heat-inactivated fetal calf serum, 100 U/mL penicillinstreptomycin, and 1% L-glutamine at 37 °C in humidified
air containing 5% CO2. Cells with 95% survival rates and
80% confluency were used in experimental analyses.
Dasatinib (BMS-35482) was provided by BristolMyers-Squibb (Princeton, NJ, USA) and dissolved in
dimethyl sulfoxide (DMSO). Experiments were generated
with 3.3 nM dasatinib treatment, indicated as the IC50
value of the K562 cell line, as well as with untreated
control group cells. After 48 h of the IC50 dose of dasatinib
treatment, cells were collected for apoptotic analyses and
miRNA profiling. Experiments were done in triplicate
with 2 separate biological replicas, and the average of the
results was taken.
2.2. Apoptotic analysis assays
The amounts of apoptotic and live cells were detected by
measuring caspase-3 activity in both untreated control
cells and cells treated with the IC50 dose of dasatinib via
the Caspase-3 Colorimetric Assay Kit (BioVision Research

Table 1. Characteristics of the K562 cell line.
Characteristics

K562

Species

Human

Tissue of origin

Blood

Source

Chronic myelogenous leukemia in terminal blast crisis

Cell type

Lymphoblast

Morphology

Population highly undifferentiated and of the granulocytic series

Cell type

Lymphoblast

Growth mode

Suspension

Karyotype

2n = 46

Culture medium

RPMI 1640 medium containing 10% (v/v) heat inactivated fetal calf serum, 100 U/mL penicillinstreptomycin, 1% L-glutamine
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Products, Mountain View, CA, USA) according to the
kit’s manual. Each sample’s absorbance was measured
spectrophotometrically at 405 nm with an ELISA reader.
Finally, apoptotic cell rates were calculated after taking the
average values of triplicated absorbance measurements for
each sample.
2.3. miRNA profiling
All 23 miRNAs chosen for the qPCR array were picked
for their potential roles in the JAK/STAT pathway and
targeted to either STAT5A or STAT5B genes. The miRTar
database (http://mirtar.mbc.nctu.edu.tw) was used for
determining appropriate miRNAs. The 3’UTR regions of
STAT5A and STAT5B gene transcripts were selected. The
analyzing parameters were in 3’UTR: MFE ≤ –14 kcal/mol
and Score ≥ 140.
Total RNA containing miRNA was isolated from cells
using the miRVana miRNA Isolation Kit (Life Technologies,
Carlsbad, CA, USA) according to the manufacturer’s
protocol. The isolated RNAs were transcribed into cDNA

by using an All-in-One First-Strand cDNA Synthesis Kit
(GeneCopoeia, Inc., Rockville, MD, USA). qPCR array
analyses were performed with the All-in-One qPCR Mix
using GeneCopoeia custom miRNA qPCR arrays on
an ABI 7500 Fast Real-Time PCR system. The miRNA
qPCR array also included RNU-2, SNORD 44, SNORD
48, SNORD 47, SNORD 49a, and SNORD 6 endogenous
controls for normalization. The list of miRNAs is given in
Table 2. All raw threshold cycle (Ct) values of the qPCR
machine-setting baseline and threshold were calculated
using SDS software v.2.1. The fold change of each miRNA
was calculated from the expression levels between
dasatinib-treated and untreated cells using the 2–ΔΔCT
method.
2.4. Validation of miRNA expression patterns
The evaluated expression profiles of miRNAs (hsamiR-940, hsa-miR-527, and hsa-miR-518a-5p) were
further validated using the All-in-One miRNA qRT-PCR
Detection Kit (GeneCopoeia). Validated primers for

Table 2. miRNA alterations in response to dasatinib treatment.
miRNA

Upregulated

Downregulated
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Fold change

P-value

hsa-miR-1224-3p

1.119

0.46556

hsa-miR-23b-3p

1.2345

0.936017

hsa-miR-550a-3p

1.3307

0.587072

hsa-miR-449b-3p

1.3338

0.065329

hsa-miR-1915-3p

1.5251

0.559666

hsa-miR-877-3p

1.6766

0.201263

hsa-miR-15a-3p

1.8241

0.887159

hsa-miR-2276-3p

2.0193

0.602148

hsa-miR-3170

2.0713

0.049475

hsa-miR-509-3-5p

2.2329

0.212423

hsa-miR-149-3p

2.2588

0.555742

hsa-miR-589-3p

2.8002

0.076596

hsa-miR-1914-3p

2.8492

0.113099

hsa-miR-4287

2.9668

0.058934

hsa-miR-23a-3p

3.6441

0.027621

hsa-miR-518a-5p

8.0401

0.0428531

hsa-miR-527

12.1304

0.041169

hsa-miR-185-5p

–1.1091

0.293338

hsa-miR-765

–1.5722

0.137123

hsa-miR-3175

–1.861

0.197593

hsa-miR-650

–2.4699

0.197252

hsa-miR-423-5p

–2.5015

0.153291

hsa-miR-1321

–3.2179

0.256309

hsa-miR-1224-5p

–3.3198

0.282529

hsa-miR-940

–4.411

0.0143376
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hsa-miR-940, hsa-miR-527, and hsa-miR-518a-5p were
purchased from GeneCopoeia; their catalog numbers
are HmiRQP0845, HmiRQP0579, and HmiRQP0579,
respectively. First-strand cDNA reaction was performed
using Techne prime thermal cyclers (Techne, Staffordshire,
UK) with samples incubated at 37 °C for 60 min and 85 °C
for 5 min to inactivate the enzyme and stored at –20 °C
until ready for use. cDNA was diluted 1:10 prior to use for
qPCR. The qPCR reactions were performed using 2X Allin-One qPCR Mix (GeneCopoeia) and an ABI 7500 Fast
Real-Time PCR system. All reactions were performed in
triplicate and analyzed using the 2–ΔΔCT method.
2.5. Statistical analyses
Statistical analyses were performed with SPSS 15.0 (SPSS
Inc., Chicago, IL, USA). Student’s t-test was used to analyze
the differences between treatment and control groups
in miRNA expression levels. P ≤ 0.05 was considered
statistically significant.
3. Results
3.1. Dasatinib triggered apoptotic cell death of leukemic
cells
The number of apoptotic cells significantly increased in
dasatinib-treated cells compared to untreated (UT) control
cells at 3.58-fold (P < 0.001) (Figure 1). This suggested that
dasatinib was very effective in triggering leukemic cell
apoptosis.
3.2. Alterations in miRNA profiling that potentially
regulate STAT5A and STAT5B
Expression profiles of selected miRNAs that potentially
regulate STAT5A and STAT5B mRNAs were evaluated
following an IC50 dose of dasatinib treatment for the study
group and untreated control cells for a duration of 48 h.
For this purpose, we detected 23 miRNAs’ expression
profiles that were selected after in silico analyses from the

Figure 1. Measurement of caspase-3 activity. Apoptosis was
significantly induced due to dasatinib treatment in leukemic
cells. UT: Untreated.

miRTar web site (http://mirtar.mbc.nctu.edu.tw). Among
these 23 miRNAs, while 8 miRNA expressions were
downregulated, ranging between –1.109-fold and –4.411fold inhibitions, 15 were upregulated, ranging between
1.119-fold and 12.13-fold regulations. All obtained data
are summarized in Table 1 and hierarchical clustering is
shown in Figure 2.
Accordingly, while there was a –4.411-fold significant
decrease in hsa-miR-940 expression (P = 0.0143) in the
dasatinib-treated group compared to untreated control
cells, an 8.0401-fold (P = 0.0428) increase in hsa-miR518a-5p expression and a 12.1304-fold increase in
has-miR-527 expression (P = 0.0411) were found. The
subsequent scatter plot and volcano plot graphics with log2
transformations are presented in Figure 3.
In the last phase of the study, we used new primer probe
sets for hsa-miR-518a-5p, hsa-miR-940, and hsa-miR-527
in order to validate the initial results regarding miRNA
expression. We detected similar results and determined that
target miRNA expressions were again significantly regulated
in dasatinib-treated cells. In detail, while hsa-miR-518a5p and hsa-miR-527 expressions were upregulated 5.78 ±
0.692-fold (P = 0.0069) and 8.337 ± 1.077-fold (P = 0.0071),
respectively, hsa-miR-940 expression was 2.85 ± 0.2516fold (P < 0.0014) downregulated (Figure 4).
4. Discussion
The JAK/STAT pathway and STAT5 in particular have
become novel molecular targets in refractory CML
patients. Permanent activation of STATs is responsible
for the development of many neoplasms, including
hematologic malignancies and solid tumors (Bowman
et al., 2000). In the case of CML, STAT5 comes into the
focus of investigation since BCR/ABL activates STAT5
proteins and causes permanent proliferation of leukemic
cells (Kosova et al., 2010; Dalgiç et al., 2015). Therefore,
molecules with an inhibitory effect on the JAK/STAT
cascade as well as STAT5A and STAT5B have attracted
significant attention with regard to their therapeutic utility
in relapsed and refractory CML patients.
miRNAs are small noncoding RNAs that control many
cellular activities by influencing cellular cascades including
JAK/STAT. In this study, we attempted to determine the
miRNAs that potentially regulate STAT5A and STAT5B
before and after dasatinib treatment. Sensitivity of K562
cells to dasatinib was evaluated by measuring caspase-3
activity. According to our results, while hsa-miR-940
expression was significantly decreased (–4.411-fold, P
= 0.0143) in the dasatinib-treated group compared to
untreated control cells, hsa-miR-518a-5p (8.0401-fold,
P = 0.0428) and hsa-miR-527 (12.1304-fold, P = 0.0411)
expressions were upregulated. These observations were
confirmed during the validation steps. We also detected
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Figure 2. Hierarchical cluster analyses of miRNA profiling. This figure was constructed by hierarchical clustering analysis. This analysis
was used to organize the miRNAs based on similarities in their expression profiles. Green indicates low expression, red indicates high
expression, and black indicates intermediate expression. UT: Untreated, T: treated.

Figure 3. miRNA profiling results in scatter plot and volcano plot graphics in log2 transformation. While red plots indicate upregulated
hsa-miR-527 and hsa-miR-518a-5p expressions, the green plot indicates downregulated hsa-miR-940.

that apoptosis was 3.58-fold upregulated following
dasatinib treatment in leukemia cells. Dasatinib-induced
apoptosis of leukemic cells has also been reported by many
authors previously (Simara et al., 2013; Heo et al., 2014;
Dalgiç et al., 2015; Ferreira et al., 2015).

930

These small molecules also have roles in the pathogenesis
of several hematopoietic malignancies (Ramkissoon et
al., 2006; Garzon et al., 2007; Dixon-McIver et al., 2008;
Troppan et al., 2014), which makes them promising targets
for treatment (Garzon et al., 2008a; Saumet et al., 2009).
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Figure 4. Validation results by qRT-PCR for hsa-miR-518a-5p, hsa-miR-940, and hsa-miR-527 expressional changes due to dasatinib
treatment.

miRNAs are not only a promising treatment approach;
they are also candidates for being prognostic indicators
(Garzon et al., 2008b) or being found to be involved in the
pathogenesis (Han et al., 2010) of acute myeloid leukemia.
They can also be target molecules in differential diagnosis
in leukemias (Mi et al., 2007). However, further research
is required to approve a specific miRNA as a diagnostic
indicator.
Since CML is a genetically well-documented
hematologic malignancy, the role of miRNA is also being
studied in CML cell lines. It was reported previously that
certain miRNAs were either downregulated or upregulated
in CML and associated with prognosis and refractory
disease. It was reported that miR150 and miR146a
were downregulated in CML and were restored after
imatinib treatment (Flamant et al., 2010). Agirre (2008)
demonstrated that miR10a expression was decreased in
bone marrow-derived CD34+ CML cells when compared

to healthy controls. miR17-5p, miR18a, and miR106a also
exhibited high expressions in chronic-phase CML, with a
change in their expression profile during the blastic phase
(Venturini et al., 2007).
Other studies in the literature demonstrated different
miRNA expressions in CML pathogenesis. Some
miRNAs’ (miR203, miR328, and miR181a) expressions
were repressed, especially during the blastic phase of
CML. Among these miRNAs, miR203 was located at the
14q32.33 chromosome; this miRNA has potential to be
a promising molecule in the treatment of CML patients,
since its genetic and epigenetic silencing is associated with
ABL1 and BCR–ABL1 oncogene expression (Bueno et al.,
2008; Eiring et al., 2010; Zimmerman et al., 2010).
One of the most important problems in CML patients
is gaining resistance to TKIs. Liu (2012) found that c-Myc
expression was upregulated; in turn, miR144/miR451
expressions were repressed in CML cell lines that were
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resistant to imatinib. This finding suggested that the
pathways and molecules inhibiting Myc expressions
or restoring miR144/miR451 expression would bypass
imatinib resistance (Liu et al., 2012). Similarly, miR424,
which directly targeted BCR–ABL1, exhibited markedly
low expression in CML lines and in patients at diagnosis.
The restoration of this miRNA suppressed proliferation
and induced apoptosis, which suggested that it could be a
potential therapeutic target in CML patients (HershkovitzRokah et al., 2015).
In the literature, the expression profiles of miRNAs
have been studied, but the precise molecular pathways
could not be very well documented. In this study, we
determined differing miRNA profiles in CML cell lines
that were potentially regulated by STAT5A and STAT5B,
which could exhibit a pivotal outcome to discover more
about CML pathogenesis.
In the literature, miR518a-5p, miR-527, and miR940 were not directly reported with leukemia-related
malignancies, especially in CML; however, in a very
recent study, miR-518a-5p was studied in imatinib
mesylate-resistant gastrointestinal stromal tumors. It
was determined that its expression was downregulated,
and PIK3C2A was reported as a gene-specific target of
miRNA-518a-5p (Shi et al., 2016). Since we have detected
that miR-518a-5p expression was upregulated in our
dasatinib-treated CML cells, we can conclude that miR518a-5p can be a promising molecular target for CML
therapy. Additionally, Rubie et al. (2014) reported that
chemokine receptor CCR6 expression was also regulated
by miR-518a-5p in colorectal cancer cells. In another
study, Port et al. (2011) reported that miR518 expression
was associated with cisplatin-resistant germ cell tumors.
According to our results, miR527 expression increased
as a result of dasatinib treatment. In a recent study, miR527 was reported to be a member of the network involved
in the regulation of physiological wound-healing responses
and was suppressed by tumor cells to promote metastatic
dissemination (Rodriguez Calleja et al., 2016).
Finally, we detected that miR-940 expression was
decreased in dasatinib-treated leukemic cells. Although
this study marks the first time that it has been put forward
that miR-940 might take place in CML pathogenesis, Liu
et al. (2015) reported that downregulation of plasma miR940 might serve as a novel biomarker for detection of
gastric cancer.
In some other recent studies, researchers claimed that
low miR-940 expressions were correlated with reduced
survival in hepatocellular carcinoma and pancreatic ductal
adenocarcinoma (Song et al., 2015; Yuan et al., 2015).
Although these reported studies seem to conflict with
our results, it is known that miRNAs can exhibit different
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effects in different cancer types; thus, it will be necessary to
study miR-940 in CML in order to clarify the exact impact.
When we look at the studies including miRNAs
in leukemia, Rokah et al. (2012) reported that miR31,
miR155, and miR564 expressions were downregulated
in CML cell line model K562 cells. They added that this
expressional downregulation was dependent on BCR–
ABL activity.
There are some other miRNAs reported to also display
therapeutic effects on CML cells by inhibiting STATs. As
an example of this phenomenon, it was reported that miR520a-5p targeted STAT3 and enhanced the antitumoral
effects of capsaicin (Kaymaz et al., 2014); in addition, miR2278 was reported as a tumor suppressor and thus a player
in the regaining of chemotherapeutic imatinib response
by targeting STAT5A in imatinib-resistant K562 leukemia
cells (Kaymaz et al., 2015).
There are also limitations to our study. This present
study reported preliminary data concerning miRNAs
regulating both STAT5A and STAT5B. The data were
obtained by a study conducted on the K562 cell line. A
study conducted with samples from CML patients should
be the next step in evaluating the role of reported miRNAs
in CML. Additionally, a second study with mimics and
inhibitors of reported miRNAs is needed to confirm the
results. Overall, our study seems to be unique since we
have evaluated the expression profiles of miRNAs that
potentially regulate STAT5A and 5B, which have a major
role in the development and progression of CML.
In conclusion, studies about the miRNAs targeting
STAT molecules and the JAK/STAT pathway are appearing
more often in the literature. We collected preliminary data
about miRNAs regulating both STAT5A and STAT5B,
and miRNAs 518a-5p, hsa-miR-527, and hsa-miR-940
were highlighted in this study for exhibiting significant
expressional changes after dasatinib treatment. We believe
these miRNAs could be promising therapeutic targets in
CML. Further studies with the inhibitors of hsa-miR-940
and the mimics of hsa-miR-527 and hsa-miR-518a-5p
should be conducted on resistant CML cells. Since it is
accepted that miRNAs exhibit very important roles in
the pathogenesis of cancers including CML, the precise
mechanism and cascades of the specific miRNAs should
be identified with new studies for more curative clinical
outcomes.
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